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Introduction
Ureteral stones account for 22 % of all urinary tract stones 
with 68 % of them being located in the distal ureter [1]. 
Conservative management strategies such as observation or 
medical expulsive therapy (MET) using pharmacological 
agents to facilitate spontaneous passage of ureteral stones 
have gained popularity in the management of ureteral 
stones during the recent years [2]. Evidence on the associa-
tion of stone size with spontaneous stone passage rates is 
scarce. 95 % of stones up to 4 mm are estimated to pass 
within 40 days. Moreover, stones <10 mm can be consid-
ered to pass spontaneously [3]. There is a growing body 
of evidence on the clinical benefit of the α-blockers in the 
patients with distal ureteral calculi. Specifically, the admin-
istration of α-blockers is related to a higher stone expulsion 
rate and shorter time periods for stone passage when com-
pared to observation [1, 4].
The mechanism of action behind the above effects is 
associated with the presence of adrenergic receptors (ARs) 
in the ureteric smooth muscle cells with the α1-adrenergic 
receptors to be the most abundant [5]. α1A-, α1B- and 
α1D-ARs are the three types of α1-ARs that are expressed 
in the human ureter with the following order of abundance 
α1D > α1A > α1B. The blocking of these receptors results 
in selective relaxation of the ureteric smooth muscle and, 
therefore, causes ureteric lumen dilatation. The latter phe-
nomenon results in facilitation of stone expulsion. [6–8].
The most commonly used α-blocker for MET is tam-
sulosin, but similar effects have been shown by other 
Abstract This study aimed at comparing the success 
rates of silodosin to the most commonly used for medical 
expulsive therapy (MET) tamsulosin for the management 
of ureteral stones. A systematic review using the search 
string: “silodosin AND (ston* OR calcu* OR expul*)” 
was conducted on Pubmed, SCOPUS, Web of Science, 
Cochrane Central Register. The Primary endpoint was the 
stone expulsion rate. Secondary endpoint was the time 
to stone expulsion. Two authors independently screened 
the studies depending on inclusion and exclusion criteria. 
Meta-analysis and forest-plot figures were calculated with 
the software Review Manager (RevMan 5.3.5). Variations 
were evaluated with the χ2 statistical method and hetero-
geneity with I2 index. After screening of 39 publications 
obtained by the initial search, three randomized controlled 
trials were eligible to be included in the meta-analysis. 
407 patients were pooled. Favorable results were observed 
for silodosin in terms of stone expulsion rates with a risk 
ratio of 1.33 (95 % CI 1.17–1.50) (I2 = 0 %). Similarly, 
faster stone expulsion times were observed with silodosin 
when compared with tamsulosin. Mean difference −2.49 
(95 % CI −3.40 to 1.58) (I2 = 89 %). This meta-analysis 
showed significantly higher stone expulsion rates and faster 
expulsion times in favor of silodosin when compared to 
tamsulosin.
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α-blockers such as terazosin and doxazosin, indicating a 
possible class effect [3]. Silodosin has been also proposed 
for MET instead of tamsulosin but studies comparing these 
substances for MET are scarce. In this systematic review 
and meta-analysis we aim to review current literature and 
compare the success rates of silodosin to tamsulosin for 
MET of ureteral stones.
Materials and methods
Search strategy and study selection
A systematic review using the search string; “silodosin 
AND (ston* OR calcu* OR expul*)” was conducted on 
Pubmed, SCOPUS, Web of Science, Cochrane Central 
Register. No restrictions were placed on language or type 
of publication. The search took place in February 2015. Eli-
gibility criteria for the meta-analysis are shown in Table 1. 
The PRISMA statement was followed for the conduction of 
the study. The Primary endpoint for the meta-analysis was 
the stone expulsion rate. Secondary endpoint was the time 
to stone expulsion.
Data extraction
Two authors independently (M. Ö. and P. K.) screened the 
studies and extracted information on study characteristics 
and outcomes. Several parameters were considered for data 
extraction. When data were missing, the authors were con-
tacted by email and additional data were requested.
Validity assessment
The quality of the studies, which were included in the 
meta-analysis, was assessed using the Jadad score [9].
Statistical analysis
Pooling of data for the meta-analysis took place for sil-
dosin compared to tamsulosin. The dichotomous data for 
each of the eligible studies were inserted in 2 × 2 table and 
expressed in the form of odds ratio (OR) or mean differ-
ence with 95 % confidence intervals (CI). Data continu-
ous in nature were pooled across studies and the weighted 
mean difference was calculated (WMD) with 95 % CI. The 
inverse variance method was used for the combination of 
the above result [10]. For the pooling of data characterized 
by a random effects model, the Der Simonian and Laird 
method was used [11].
Meta-analysis and forest-plot figures were calculated 
with the software Review Manager (RevMan 5.3.5) of 
the Cochrane Collaboration. Variations among the studies 
were evaluated using the χ2 statistical method. I2 index was 
calculated to show the proportion of inconsistency among 
the studies that could not be attributed to chance. Values 
≥50 % were considered as significant heterogeneity [12]. 
A fixed effect model was used when the statistical hetero-
geneity did not achieve significance while a random effects 
model was used in the case of high heterogeneity. Statisti-
cal significance was set at p values of 0.05. The publica-
tion bias was assessed with the use of funnel plots and the 
Egger’s test [13, 14].
Results
Selection of studies
After eliminating duplicates, two aforementioned investiga-
tors screened an initial number of 39 publications by their 
title according to eligibility criteria. Discrepancies were 
resolved by consensus among the investigators. 11 publica-
tions, which passed the first elimination, were then screened 
by their abstracts according to the eligibility criteria. Eight 
studies were excluded (two conference abstract, one obser-
vational retrospective study, three studies from the same 
study group without tamsulosin group, one study with pla-
cebo as control group and one study with silodosin com-
pared to naftopidil after shock wave lithotripsy therapy). 
Finally, only three randomized controlled trials (RCT) were 
eligible to be included in the meta-analysis (Fig. 1).
Study characteristics
The three RCTs that were eligible for the meta-analysis 
were published between 2013 and 2014. In all of these 
studies a daily dosage of 8 mg of silodosin was com-
pared with a daily dosage of 0.4 mg of tamsulosin. Two 
of these studies were double-blinded. Study design and 
Table 1  Inclusion and exclusion criteria
Inclusion criteria
 Ureteral stones
 RCTs and MET
 Comparison silodosin vs tamsulosin
 Follow-up at least 14 days
Exclusion criteria
 Kidney and bladder stones
 Asymmetrical co-interventions (i.e. swl, JJ stent)
 No comparison arm
 Abstracts
 Animal studies
 Follow-up <14 days
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treatment protocol characteristics as well as study results 
are described in Table 2. A detailed description of side 
effects was reported in two studies (Table 3).
Quality assessment of the studies
Jadad score calculations depending on randomization, 
blinding and definition of dropouts revealed jaded score >3 
for all of the three RCTs.
Description of the included studies results
All three authors responded to our requests, but unfortu-
nately data especially on side effects profile and number of 
colic episodes were not available for all studies.
Dell’Atti et al. [15] enrolled 136 consecutive patients 
with solitary lower ureteral stones. Patients were rand-
omized into two groups receiving either silodosin or tamsu-
losin. Four patients dropped out due to orthostatic hypoten-
sion after 1 week of medication and were excluded from 
the statistical analysis. After contacting the authors we have 
learned that ureteroscopic stone removal was performed 
on these dropout patients. The silodosin group showed an 
expulsion rate of 80.3 % whereas the tamsulosin group 
showed an expulsion rate of 61.2 % (p = 0.003). In the silo-
dosin group, 25 patients (47.1 %) passed their stones within 
the first week of treatment, 21 patients (39.7 %) within 
2 weeks and seven patients (13.2 %) within 3 weeks of 
treatment. 13 (31.7 %), 16 (39 %) and 12 (29.3 %) patients 
passed their stones in the tamsulosin group within 1, 2 and 
3 weeks, respectively, resulting in a significant advantage 
in favor of silodosin (p = 0.002).
The second RCT, which was included in the meta-anal-
ysis consisted of three groups with 90 patients each [16]. 
270 patients were randomized to receive 8 mg of silo-
dosin, 0.4 mg of tamsulosin or 10 mg of tadalafil. Only 
data regarding the silodosin and tamsulosin groups were 
included in the analysis. The stone expulsion rate was 
83.3 % in the silodosin group and 64.4 % in the tamsu-
losin group. Silodosin showed superior stone expulsion 
rates when compared with tamsulosin (83.3 vs 64.4 % 
p = 0.006) [16].
In the third RCT, 100 patients with unilateral uncompli-
cated middle or lower ureteral stones ≤1 cm were enrolled 
and randomized into silodosin and tamsulosin groups [17]. 
The silodosin group had significantly higher stone expul-
sion rates after a follow-up of 4 weeks when compared to 
tamsulosin group, 41/50 (82 %) patients and 29/50 (58 %) 
patients, respectively (p = 0.008). There was also a signifi-
cant difference between the two groups in terms of mean 
stone expulsion time with 12.5 ± 3.5 vs. 19.5 ± 7.5 days 
in silodosin and tamsulosin groups, respectively (p = 0.01).
Quantitative analysis
The current meta-analysis included 407 pooled patients 
after the elimination of the dropouts. The pooling of the 
data showed favorable results for silodosin in terms of 
stone expulsion rates with a risk ratio of 1.33 (95 % CI 
1.17, 1.50) and lack of heterogeneity (I2 = 0 %). Patients, 
who were treated with silodosin, had faster stone expulsion 
times when compared with tamsulosin. Mean difference 
−2.49 (95 % CI: −3.40, −1.58) for the silodosin group. 
Nevertheless, the heterogeneity of the studies included in 
the pooled analysis was high (I2 = 89 %) (Fig. 2).
Discussion
Tamsulosin is a selective α1-blocker with tenfold greater 
affinity to α1A- and α1D- AR subtypes in comparison to 
α1B -AR subtype, whereas the affinity of silodosin to 
α1A-AR subtype is about 162-fold and 50-fold greater 
Fig. 1  Study design
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than its affinity to α1B- and α1D-AR subtypes, respectively 
[18]. Silodosin has shown superior results in the treatment 
of benign hyperplasia of the prostate when compared with 
tamsulosin in terms of efficacy and safety [19]. The above 
differences in the affinity of the tamsulosin and silodosin 
to the respective receptors may be related to the observed 
differences in the clinical outcome of these pharmaceutical 
substances for MET.
The expulsive effect for ureteral stones of silodo-
sin has been proposed in a RCT comparing silodosin to 
observation treatment [20]. 112 patients were randomized 
into 8 mg of silodosin or observation. Both groups were 
directed to take 2 L of water/day. Silodosin showed supe-
rior expulsion rates especially for stones ≥5 mm. The 
stones of 17.9 % (n = 28) of the patients of the observa-
tion group and 75.9 % (n = 29) of the silodosin group 
were successfully expelled (p = 0.001). The expulsion 
time was 13.40 ± 5.90 and 9.29 ± 5.91 days, respectively 
(p = 0.012). Analgesics were required 1.5 ± 3.1 and 
0.3 ± 0.9 times, respectively (p = 0.382). The stone size 
of the expulsion cases showed significant difference with 
3.64 ± 1.25 and 5.23 ± 2.32 mm for the observation and 
silodosin groups, respectively (p = 0.003). The authors 
concluded that the administration of silodosin facilitated 
the expulsion of 1.5 mm or larger distal ureteral stones, as 
compared to the control group which did not include any 
medical intervention for stone expulsion [20].
The available evidence in the literature regarding the 
superiority of silodosin over tamsulosin for the MET of 
ureteral stones has been controversial. One of the studies 
that compare the effect of silodosin to the most commonly 
used substance for MET was reported by Imperatore et al. 
[21] The investigators retrospectively collected observa-
tional data from patients who received either silodosin or 
tamsulosin within a period of 1 year. The authors found no 
significant difference between the two groups in terms of 
Table 3  Side effects
ns not-significant 
Type of MET Study Study
Dell’Atti [15] Dell’Atti [15] p Kumar [16] Kumar [16] p
Silodosin Tamsulosin Silodosin Tamsulosin
Side effects
 Retrograde ejaculation 22.7 % (10/44) 10.2 % (4/39) <0.00 15.6 (10/64) 11.2 (7/62) ns
 Orthostatic hypotension 3 % (2/66) 1.5 % (1/67) ns 3.3 % 6.6 % ns
 Headache 1.5 % (1/66) 1.5 % (1/67) ns 12.2 % 10.0 % ns
 Dizziness 6 % (4/66) 4.5 % (3/67) ns 8.8 % 10 % ns
Expulsion Rates
Time to Expulsion
Fig. 2  Forest plot analysis
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stone expulsion rates (88 and 82 %, respectively) or mean 
stone expulsion times (6.7 and 6.5 days, respectively). Nev-
ertheless, the inclusion of 50 patients in each group, despite 
the retrospective nature of this study, raised the question of 
a possible selection bias. Due to its retrospective nature, the 
above study was not included in the current meta-analysis.
Another study not included in the current meta-analysis 
was conducted by Rathi et al. [22] The study was presented 
as an abstract in an International Congress. The investi-
gators randomized 87 patients with distal ureteral stones 
of <10 mm into three groups. Group I (n = 29) received 
8 mg silodosin daily, group II (n = 30) received 0.4 mg 
tamsulosin daily and group III patients (n = 28) were not 
given any of the above substances. Patients in all groups 
received diclofenac sodium regularly for 1 week and then 
on demand. The follow-up period was 4 weeks. The stone 
expulsion rates for groups I, II and III were 86.2, 76.6 and 
50 %, respectively. The difference in groups I and II with 
respect to group III was significant (p = 0.0028 and 0.035, 
respectively). The expulsion time was significantly shorter 
in groups I and II than in group III (p = 0.0097 and 0.026, 
respectively). Patients taking silodosin and tamsulosin had 
fewer pain attacks than group III patients. No side effects 
were reported in silodosin or tamsulosin groups.
The authors concluded the use of α-blockers for MET of 
lower ureteric stones to be safe and effective without any 
significant benefit of silodosin over tamsulosin.
On contrast to the above studies, the current meta-anal-
ysis showed superior stone expulsion rates and faster stone 
expulsion times for silodosin when compared with tamsu-
losin. Our pooled data showed a lack of heterogeneity for 
the expulsion rate calculations with an I2 value of 0 % indi-
cating reliable results. On the other hand, a high level of 
heterogeneity was calculated for stone expulsion times with 
an I2 value of 89 %, but I2 can be misleading as the mag-
nitude and directions of the effects may influence its value 
and the p value from the χ2 test or the CI may be related to 
strength of evidence of heterogeneity. When the p value of 
the χ2 (p < 0.0001) and the CI [−2.49 (−3.40, −1.58)] are 
considered, it is clear that the expulsion time is shorter for 
silodosin in the current analysis. Moreover, the quality of 
the included studies was high according to the Jadad score 
(>3). When considering the low heterogeneity and the qual-
ity of the included studies, the presented results in favor 
of silodosin should probably be considered as reliable and 
accurate.
A similar meta-analysis was published recently evaluat-
ing the efficacy and safety of silodosin for MET [23]. In 
contrast to the current meta-anlaysis, seven studies were 
included. Two of the included studies were conducted by 
the same working group (Itoh et al.) and were published 
with a difference of 2 years. The investigators did not 
indicate in these two studies the time period for patient 
recruitment and it is likely that these studies may be over-
lapping. In addition, the aforementioned study by Impera-
tore et al. is not a RCT but a retrospective observational 
study which reduces the quality of the included studies. As 
a result, we could advocate that the current meta-analysis 
provided evidence of higher quality despite the low number 
of studies which were included. In fact, the latter issue is 
probably the major drawback of the current meta-analysis. 
Nevertheless, the low level of heterogeneity detected by I2 
test, especially for the primary endpoint, renders the cur-
rent data to be representative. Larger scale RCTs are neces-
sary for the confirmation of the current findings.
An important aspect of MET is the effect in the reduc-
tion of colic episodes. Kumar et al. [16] advised their 
patients to receive 50 mg of diclofenac on demand during 
MET. The mean number of pain episodes for the silodosin 
group was significantly lower than that for the tamsulosin 
group, 0.8 (SD ± 0.9) and 1.7 (SD ± 1.2), respectively 
(p < 0.001). A significantly lower requirement of analgesia 
was noted for silodosin (mean = 195 ± 10.2 mg) in com-
parison to tamsulosin (mean = 220 ± 10.8 mg) (p < 0.001). 
Similarly, Gupta et al. [17] was able to demonstrate lower 
analgesic use for the silodosin group. On the contrary, 
Imperatore et al. [21] showed no significant difference in 
terms of mean number of pain episodes and need for anal-
gesics while Dell’atti et al. [15] reported infrequent and 
mild colic episodes in both groups that were manageable 
with analgesics that allowed continuation of MET. Thus, 
a possible but not clear reduction of colic events could be 
advocated for silodosin in comparison to tamsulsosin.
The evaluation of side effects is an important aspect of 
any medical therapy. In the case of silodosin and tamsulo-
sin, abnormal ejaculation was the most predominant side 
effect observed for both silodosin and tamsulosin [15–17]. 
This difference was significant in the study of Dell’Atti 
et al. [15] which showed a significantly higher incidence 
of abnormal ejaculation in the silodosin group in compari-
son to the tamsulosin group with 22.7 and 10.2 % of the 
patients having experienced the side effect, respectively 
(p < 0.002). Imparatore et al. [21] also demonstrated a 
significantly higher incidence of abnormal ejaculation in 
the silodosin group when compared to tamsulosin group 
(p < 0.05). In the remaining studies, the difference among 
the two substances did not reach any significance. Other 
common side effects for both groups were orthostatic 
hypotension, headache, dizziness and diarrhea without any 
statistical difference or clinical consequence [15–17]. On 
the other hand, a significantly lower incidence of periph-
eral vasodilatation-related complications was observed for 
the silodosin group when compared to the patients who 
received tamsulosin [17, 21]. Considering the above evi-
dence, it seems that the use of silodosin may be related to a 
higher incidence of ejaculation disturbances in comparison 
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to the use of tamsulosin without any other significant dif-
ference in the side effects. The ejaculatory issues represent 
side effects that are reversible after the withdrawal from the 
MET and may not compromise the general health of the 
patients. Thus, the use of either substances for MET could 
be considered as safe.
Conclusion
The current meta-analysis showed significantly higher stone 
expulsion rates and faster expulsion times in favor of silodo-
sin when compared with tamsulosin. Both of these medica-
tions demonstrated a good safety and tolerability profile for 
MET in patients with uncomplicated ureteral stones. Further 
RCTs would strengthen the presented evidence.
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